Avagene is developing Bodhi — a closed, compact incubator platform that preserves 2D workflows while adding AI-driven microscopy, programmable microenvironments, and electronic batch records.
Adherent HEK293 production is driven by confluence, timing, and handling — small deviations drive large differences in yield and quality. Switching platforms to gain scale (fixed-bed, suspension) forces comparability work that penalizes startups and academic groups.
Avagene's approach: standardize and close the adherent workflow while adding automation, computer vision, and immutable batch records — so the process that proves feasibility is the same process that scales.
HEPA-filtered enclosure, sterile quick-connects, peristaltic pumps, UV/chemical sanitation, independent roller-bottle lanes with programmable agitation.
Embedded phase + fluorescence imaging, NIST-traceable calibration, confluence and transfection quantification with uncertainty — cross-validated across serotypes and lighting.
Immutable, hash-verified export of environmental logs, imaging data, and process events — built for clean tech transfer and a path to GMP.
Avagene's Phase I plan is executed in collaboration with Temple University (subaward to Dr. George M. Smith at the Shriners Pediatric Research Center) and draws support from established clinical, advanced-therapy, and biotech partners.
Avagene maintains policies consistent with the PHS Financial Conflict of Interest regulations (42 CFR Part 50, Subpart F). Our FCOI policy is publicly accessible and applies to all investigators on PHS-funded research.